Executives On The Move: A New CEOs for ACADIA Pharmaceuticals And G1 Therapeutics Among This Week's Changes

​​​

Executive Summary​​

​​

Other recent moves in the industry include changes at the top at Adocia, CSL and Entrada Therapeutics.

Executives on the Move.
• Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Leadership

ProGen’s Dual Agonist Obesity Contender Gains Momentum With Rani Partnership

 
• By 

The CEO of South Korean biotech shares how his company was able to reach a partnership with Rani so quickly and why it is confident in its GLP-1/GLP-2 dual agonist for obesity and diabetes, despite recent disappointing clinical results for its sole rival.

Scrip-Leadership (Free-2): Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

 
• By 

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.

As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS

 
• By 

Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.

Novo Nordisk’s Semaglutide Shows Promise In Hidradenitis Suppurativa

 

An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.

More from Executives On The Move

Executives On The Move: A New CEOs for ACADIA Pharmaceuticals And G1 Therapeutics Among This Week's Changes

 
• By 

​​​<p>Executive Summary​​ </p> ​​<br> <p>Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements</p>

Quick Listen: Scrip's Five Must-Know Things

 
• By 

In this week's podcast edition of Five Must-Know Things: CMS’s price reveal better than expected?; new diabetes risk data for Zepbound; can J&J’s lung cancer combo stand up to Tagrisso?; new recruits for BioMarin leadership; and Glenmark’s shifting revenues.

Executives On The Move: Fulcrum Therapeutics Acquires Chief Commercial Officer From ImmunoGen

 
• By 

Recent moves in the industry include C-suite shuffle at Perspective Therapeutics and Bausch Health, plus Oculis Holding gets a new CDO and Tiziana Life Sciences gets a new CEO.